The quest for effective weight loss strategies has led to some fascinating discoveries, but a recent study reveals a surprising truth: surgery is still king when it comes to shedding pounds. And it's not even close!
Researchers from New York University (NYU) compared two surgical procedures, sleeve gastrectomy and gastric bypass, to the popular weight loss medications, semaglutide and tirzepatide. These drugs, known as GLP-1 receptor agonists, mimic the natural GLP-1 hormone, which controls appetite. By analyzing health records, the team matched individuals who had taken these medications with those who underwent bariatric surgery, ensuring a fair comparison based on age, BMI, and blood sugar levels.
The results were eye-opening. Over two years, the surgery group shed an impressive 25.7% of their total body weight, while those relying on medication only managed a 5.3% loss. This disparity can be attributed to patients' adherence to their GLP-1 drugs, as surgery provides a more permanent solution. But here's where it gets controversial: even over shorter periods, surgery consistently delivered better results.
NYU surgical resident Avery Brown, presenting the findings in June, highlighted that clinical trials show weight loss of 15-21% for GLP-1s, but real-world results are significantly lower, even for those with active prescriptions for a year. Brown suggests that GLP-1 patients should adjust their expectations, adhere more strictly to treatment, or consider metabolic and bariatric surgery for desired outcomes.
It's worth noting that the study was funded by the American Society for Metabolic and Bariatric Surgery (ASMBS), which has a vested interest in promoting surgical options. However, the researchers aren't dismissing semaglutide treatments, which also showed benefits. With GLP-1 prescriptions on the rise, it's crucial to understand how they compare to established surgical methods and determine the best options for individuals.
ASMBS President Ann M. Rogers, not involved in the study, emphasized, "While both patient groups lose weight, metabolic and bariatric surgery is much more effective and durable." Despite this, GLP-1 drugs remain more popular, but adherence is an issue, with many patients discontinuing treatment within a year. Meanwhile, only a small percentage of eligible individuals opt for surgery.
But weight loss is just one aspect. Ozempic, a semaglutide medication, was originally approved for type 2 diabetes, as it helps lower blood sugar levels. Studies also suggest it reduces the risk of cancer and cardiovascular disease. In this study, bariatric surgery showed even better blood sugar control.
While surgery is a powerful tool, it's not without its challenges. Invasive and permanent, it still requires strict diet and exercise routines. NYU bariatric surgeon Karan Chhabra plans to identify ways to optimize GLP-1 outcomes, determine which patients are better suited for surgery or GLP-1s, and assess the role of out-of-pocket costs in treatment success. The research was presented at the ASMBS annual meeting in 2025.
So, is surgery the ultimate answer for weight loss and improved health? Or do GLP-1 drugs offer a more accessible, less invasive solution? What do you think? We'd love to hear your thoughts in the comments!
